RIGI and dengue disease: RIG-I agonists have been shown to provide protection in murine models of influenza virus and Dengue virus infection (61,62), and 5′ triphosphorylated dsRNAs have been shown to promote greater increases in specific antibody titers elicited by influenza virus like-particles or influenza vaccine administration than currently approved adjuvants (63,64).